<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9825">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05689463</url>
  </required_header>
  <id_info>
    <org_study_id>2020/0429/HP</org_study_id>
    <nct_id>NCT05689463</nct_id>
  </id_info>
  <brief_title>Evaluation of the Prevalence of BP180 and BP230 Autoantibodies in the Serum of Patients With Pruritus Under Immunotherapy</brief_title>
  <acronym>BPA_immun</acronym>
  <official_title>Evaluation of the Prevalence of BP180 and BP230 Autoantibodies in the Serum of Patients With Pruritus Under Immunotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Rouen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the prevalence of positive anti BP180 and/or anti BP230&#xD;
      serology in the serum of patients with chronic and diffuse pruritus for at least 1 month&#xD;
      under immunotherapy and in the absence of obvious pruritic dermatosis (e.g. scabies, contact&#xD;
      eczema...).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 23, 2023</start_date>
  <completion_date type="Anticipated">January 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">February 23, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients on immunotherapy with chronic diffuse pruritus for at least 1 month with positive anti BP180 and/or anti BP230 serology</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of anti-BP180 and/or anti-BP230 positive patients who will develop urticarial, eczematous or bullous disease</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of anti-BP180 and/or anti-BP230 positive patients who will develop urticarial, eczematous or bullous disease</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Patients With Chronic Pruritus for More Than 1 Month Who Have Received Immunotherapy</condition>
  <arm_group>
    <arm_group_label>Patient with prurit</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>characterisation of immunoglobulin subclasses</intervention_name>
    <description>For patients with positive anti BP180 and/or anti BP230 serology, a characterisation of the immunoglobulin subclasses will be performed</description>
    <arm_group_label>Patient with prurit</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient currently receiving immunotherapy (pembrolizumab, nivolumab, atezolizumab,&#xD;
             durvalumab) as monotherapy or in combination OR patient who has received immunotherapy&#xD;
             (pembrolizumab, nivolumab, atezolizumab, durvalumab) as monotherapy or in combination&#xD;
             within the last 6 months.&#xD;
&#xD;
          -  Patients with chronic (&gt; 1 month) diffuse pruritus, which started after the start of&#xD;
             immunotherapy and in the absence of an obvious pruritic dermatosis.&#xD;
&#xD;
          -  Woman of childbearing age with effective contraception (see GTFG) (estrogen-progestin&#xD;
             or intrauterine device or tubal ligation) for 1 month (negative urine/blood pregnancy&#xD;
             test) or Postmenopausal woman: confirmatory diagnosis (non-medically induced&#xD;
             amenorrhea for at least 12 months prior to the inclusion visit)&#xD;
&#xD;
          -  Major patient&#xD;
&#xD;
          -  Patient having read and understood the information letter and signed the consent form&#xD;
&#xD;
          -  Patient affiliated to a social security scheme&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Pruritus prior to immunotherapy. Bullous pemphigoid prior to immunotherapy End-stage&#xD;
        chronic renal failure (GFR &lt; 15ml/min or dialysis) Clinical jaundice or total bilirubin &gt;&#xD;
        34 µmol/L Hepatic cholestasis Diabetes mellitus complicated by diabetic neuropathy. History&#xD;
        of polycythemia vera History of Hodgkin's lymphoma iron deficiency anemia Current treatment&#xD;
        including DPP-4 inhibitors (vildagliptin, linagliptin) Treatment with systemic&#xD;
        corticosteroids or immunosuppressant for more than one month.&#xD;
&#xD;
        Pregnant or parturient or breastfeeding woman or absence of proven contraception&#xD;
&#xD;
        · Person deprived of liberty by an administrative or judicial decision or person placed&#xD;
        under legal safeguard / sub-tutorship or curatorship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vivien HEBERT, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rouen University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vivien HEBERT, MD</last_name>
    <phone>02 32 88</phone>
    <phone_ext>89 90</phone_ext>
    <email>vivien.hebert@chu-rouen.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Armelle GUIDOTTI</last_name>
    <phone>023288</phone>
    <phone_ext>8265</phone_ext>
    <email>armelle.guidotti@chu-rouen.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UHRouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivien Hebert, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2023</verification_date>
  <study_first_submitted>January 9, 2023</study_first_submitted>
  <study_first_submitted_qc>January 9, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2023</study_first_posted>
  <last_update_submitted>May 23, 2023</last_update_submitted>
  <last_update_submitted_qc>May 23, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pruritus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

